Exelixis, Inc. Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients With Progressive, Metastatic Medullary Thyroid Cancer

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of additional data from clinical trials of COMETRIQ™ (cabozantinib) in patients with progressive, metastatic medullary thyroid cancer (MTC). The data were presented this weekend at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Long-term follow-up of a phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic MTC patients treated with COMETRIQ experienced disease control (DC) and have remained progression-free for more than 2 years. A separate presentation (Abstract #6000) reports data from the prospective analysis of RET mutational status and retrospective ad hoc analysis of RAS mutational status of patients in EXAM, Exelixis’ phase 3 pivotal trial of COMETRIQ in progressive, metastatic MTC. These data show improvement in progression-free survival (PFS) with COMETRIQ treatment compared to placebo in all genetically defined subgroups, with a greater effect on PFS seen in the RET mutation positive and RET mutation unknown subgroups. The U.S. Food & Drug Administration approved COMETRIQ for the treatment of progressive, metastatic MTC in November 2012. The label allows for use of COMETRIQ in progressive, metastatic MTC without regard to mutation status.

Help employers find you! Check out all the jobs and post your resume.

Back to news